Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin

First Posted Date
2010-10-25
Last Posted Date
2014-05-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
502
Registration Number
NCT01227629
Locations
🇺🇸

1160.20.10015, Baltimore, Maryland, United States

🇩🇰

1160.20.45010, Aalborg, Denmark

🇩🇰

1160.20.45005 Aarhus Sygehus, Aarhus C, Denmark

and more 35 locations

A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin

First Posted Date
2010-10-04
Last Posted Date
2013-01-29
Lead Sponsor
AstraZeneca
Registration Number
NCT01214122
Locations
🇸🇪

Research Site, Uppsala, Sweden

A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-09-10
Last Posted Date
2011-02-09
Lead Sponsor
AstraZeneca
Target Recruit Count
28
Registration Number
NCT01199341
Locations
🇸🇪

Research Site, Uppsala, Sweden

Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

First Posted Date
2010-08-16
Last Posted Date
2018-07-26
Lead Sponsor
Boston Scientific Corporation
Target Recruit Count
407
Registration Number
NCT01182441
Locations
🇺🇸

St. John's Hospital / Pacific Heart, Santa Monica, California, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Cardiology Associates of N. Mississippi, Tupelo, Mississippi, United States

and more 37 locations

A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin

First Posted Date
2010-06-03
Last Posted Date
2014-03-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
174
Registration Number
NCT01136408
Locations
🇯🇵

1160.49.014 Boehringer Ingelheim Investigational Site, Suita, Osaka, Japan

🇯🇵

1160.49.027 Boehringer Ingelheim Investigational Site, Iizuka,Fukuoka, Japan

🇯🇵

1160.49.013 Boehringer Ingelheim Investigational Site, Kyoto, Kyoto, Japan

and more 25 locations

A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

First Posted Date
2010-05-28
Last Posted Date
2016-08-03
Lead Sponsor
Kastle Therapeutics, LLC
Target Recruit Count
18
Registration Number
NCT01133366
Locations
🇺🇸

PPD Development, LP, Austin, Texas, United States

Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-05-25
Last Posted Date
2014-06-16
Lead Sponsor
LEO Pharma
Target Recruit Count
900
Registration Number
NCT01130025
Locations
🇨🇦

Diamond Health Care Centre, Vancouver, British Columbia, Canada

Evaluation of Maintenance Dosing vs Loading Dosing Upon Restarting Warfarin Therapy: A Prospective Randomized Trial

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-05-14
Last Posted Date
2017-10-25
Lead Sponsor
University of Alberta
Target Recruit Count
39
Registration Number
NCT01124058
Locations
🇨🇦

Univeristy of Alberta, Edmonton, Alberta, Canada

Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

First Posted Date
2010-04-27
Last Posted Date
2014-07-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
18
Registration Number
NCT01111331
Locations
🇩🇪

1245.18.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

© Copyright 2024. All Rights Reserved by MedPath